209 related articles for article (PubMed ID: 35040682)
21. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.
Gebhart G; Lamberts LE; Wimana Z; Garcia C; Emonts P; Ameye L; Stroobants S; Huizing M; Aftimos P; Tol J; Oyen WJ; Vugts DJ; Hoekstra OS; Schröder CP; Menke-van der Houven van Oordt CW; Guiot T; Brouwers AH; Awada A; de Vries EG; Flamen P
Ann Oncol; 2016 Apr; 27(4):619-24. PubMed ID: 26598545
[TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.
Lu D; Girish S; Gao Y; Wang B; Yi JH; Guardino E; Samant M; Cobleigh M; Rimawi M; Conte P; Jin JY
Cancer Chemother Pharmacol; 2014 Aug; 74(2):399-410. PubMed ID: 24939213
[TBL] [Abstract][Full Text] [Related]
23. An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer.
Lu D; Joshi A; Wang B; Olsen S; Yi JH; Krop IE; Burris HA; Girish S
Clin Pharmacokinet; 2013 Aug; 52(8):657-72. PubMed ID: 23553425
[TBL] [Abstract][Full Text] [Related]
24. Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer.
Bellon JR; Tayob N; Yang DD; Tralins J; Dang CT; Isakoff SJ; DeMeo M; Burstein HJ; Partridge AH; Winer EP; Krop IE; Tolaney SM
Int J Radiat Oncol Biol Phys; 2022 May; 113(1):117-124. PubMed ID: 34990776
[TBL] [Abstract][Full Text] [Related]
25. Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer.
Lambert JM; Chari RV
J Med Chem; 2014 Aug; 57(16):6949-64. PubMed ID: 24967516
[TBL] [Abstract][Full Text] [Related]
26. Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis.
Salvestrini V; Kim K; Caini S; Alkner S; Ekholm M; Skyttä T; Becherini C; Coles CE; Kaidar-Person O; Offersen B; de Azambuja E; Visani L; Cortes J; Harbeck N; Rugo HS; Isacke CM; Marangoni E; Morandi A; Lambertini M; Poortmans P; Livi L; Meattini I
Radiother Oncol; 2023 Sep; 186():109805. PubMed ID: 37437610
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of the addition of pertuzumab to T-DM1 ± taxane in patients with HER2-positive, locally advanced or metastatic breast cancer: a pooled analysis.
Zhang J; Li J; Zhu C; Song Y; Xia F; Ma X
Drug Des Devel Ther; 2017; 11():3235-3244. PubMed ID: 29180848
[TBL] [Abstract][Full Text] [Related]
28. STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer.
Wang L; Wang Q; Gao M; Fu L; Li Y; Quan H; Lou L
Cancer Sci; 2018 Oct; 109(10):3305-3315. PubMed ID: 30076657
[TBL] [Abstract][Full Text] [Related]
29. The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer.
Delgado J; Vleminckx C; Sarac S; Sosa A; Bergh J; Giuliani R; Enzmann H; Pignatti F
ESMO Open; 2021 Apr; 6(2):100074. PubMed ID: 33647599
[TBL] [Abstract][Full Text] [Related]
30. Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1).
Diessner J; Bruttel V; Stein RG; Horn E; Häusler SF; Dietl J; Hönig A; Wischhusen J
Cell Death Dis; 2014 Mar; 5(3):e1149. PubMed ID: 24675467
[TBL] [Abstract][Full Text] [Related]
31. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
Patel TA; Ensor JE; Creamer SL; Boone T; Rodriguez AA; Niravath PA; Darcourt JG; Meisel JL; Li X; Zhao J; Kuhn JG; Rosato RR; Qian W; Belcheva A; Schwartz MR; Kaklamani VG; Chang JC
Breast Cancer Res; 2019 Sep; 21(1):100. PubMed ID: 31477168
[TBL] [Abstract][Full Text] [Related]
32. Development and responses of brain metastases during treatment with trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer: A single institution experience.
Okines A; Irfan T; Khabra K; Smith I; O'Brien M; Parton M; Noble J; Stanway S; Somaiah N; Ring A; Johnston S; Turner N
Breast J; 2018 May; 24(3):253-259. PubMed ID: 28833867
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer.
Lu D; Li C; Riggs M; Polhamus D; French J; Agarwal P; Chen SC; Vadhavkar S; Patre M; Strasak A; Quartino A; Jin JY; Girish S
Cancer Chemother Pharmacol; 2019 Jul; 84(1):175-185. PubMed ID: 31102024
[TBL] [Abstract][Full Text] [Related]
34. Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort.
Akyildiz A; Guven DC; Yildirim HC; Ismayilov R; Yilmaz F; Tatar OD; Chalabiyev E; Kus F; Yalcin S; Aksoy S
Medicine (Baltimore); 2023 May; 102(18):e33677. PubMed ID: 37145008
[TBL] [Abstract][Full Text] [Related]
35. Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy.
Molinelli C; Parisi F; Razeti MG; Arecco L; Cosso M; Fregatti P; Del Mastro L; Poggio F; Lambertini M
Expert Rev Anticancer Ther; 2021 Mar; 21(3):241-250. PubMed ID: 33245671
[No Abstract] [Full Text] [Related]
36. Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series.
Sibaud V; Niec RE; Schindler K; Busam KJ; Roché H; Modi S; Delord JP; Lacouture ME
Breast Cancer Res Treat; 2014 Jul; 146(2):451-6. PubMed ID: 24929675
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).
Ruddy KJ; Zheng Y; Tayob N; Hu J; Dang CT; Yardley DA; Isakoff SJ; Valero VV; Faggen MG; Mulvey TM; Bose R; Sella T; Weckstein DJ; Wolff AC; Reeder-Hayes KE; Rugo HS; Ramaswamy B; Zuckerman DS; Hart LL; Gadi VK; Constantine M; Cheng KL; Briccetti FM; Schneider BP; Merrill Garrett A; Kelly Marcom P; Albain KS; DeFusco PA; Tung NM; Ardman BM; Nanda R; Jankowitz RC; Rimawi M; Abramson V; Pohlmann PR; Van Poznak C; Forero-Torres A; Liu MC; Rosenberg S; DeMeo MK; Burstein HJ; Winer EP; Krop IE; Partridge AH; Tolaney SM
Breast Cancer Res Treat; 2021 Aug; 189(1):103-110. PubMed ID: 34120223
[TBL] [Abstract][Full Text] [Related]
38. Telangiectasia and Pulmonary Arterial Hypertension Following Treatment With Trastuzumab Emtansine: A Case Report.
Kwon Y; Gomberg-Maitland M; Pritzker M; Thenappan T
Chest; 2016 Apr; 149(4):e103-5. PubMed ID: 27055712
[TBL] [Abstract][Full Text] [Related]
39. Corneal features in trastuzumab emtansine treatment: not a rare occurrence.
Deklerck E; Denys H; Kreps EO
Breast Cancer Res Treat; 2019 Jun; 175(2):525-530. PubMed ID: 30820718
[TBL] [Abstract][Full Text] [Related]
40. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.
Boyraz B; Sendur MA; Aksoy S; Babacan T; Roach EC; Kizilarslanoglu MC; Petekkaya I; Altundag K
Curr Med Res Opin; 2013 Apr; 29(4):405-14. PubMed ID: 23402224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]